Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

2021801 citationsJournal Articlebronze Open Access

Authors

Raphael J. Landovitz · University of California, Los Angeles

Deborah Donnell · Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa

Meredith E. Clement · UCLA Medical Center

Brett Hanscom · Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa

Leslie Cottle · Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa

Lara E. Coelho · UCLA Medical Center

Abstract

CAB-LA was superior to daily oral TDF-FTC in preventing HIV infection among MSM and transgender women. Strategies are needed to prevent INSTI resistance in cases of CAB-LA PrEP failure. (Funded by the National Institute of Allergy and Infectious Diseases and others; HPTN 083 ClinicalTrials.gov number, NCT02720094.).

Topics & Keywords

HIV/AIDS Research and Interventions HIV Research and Treatment HIV-related health complications and treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 385, Issue 7, pp. 595-608

DOI: 10.1056/nejmoa2101016

Field-Weighted Citation Impact: 35.92